The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

AIDS
D J KempfJ M Leonard

Abstract

To determine markers that are associated with the durability of virologic response to therapy with HIV protease inhibitors in HIV-infected individuals. This study encompassed two retrospective analyses of the duration of virologic response to protease inhibitor therapy. The first analysis included 29 patients receiving either monotherapy or combination therapy with the protease inhibitor ritonavir whose plasma HIV RNA levels rebounded from the point of greatest decline with mutations associated with resistance to ritonavir. The second analysis included a cohort of 102 patients who initially responded to randomized treatment with either monotherapy with ritonavir or combination therapy with ritonavir and zidovudine. Durability of response was defined as the time from the initiation of therapy to the point at which plasma HIV RNA displayed a sustained increase of at least 0.6 log10 copies/ml from the nadir value. In the first analysis, durability of response was analyzed with respect to baseline HIV RNA, HIV RNA at the nadir, and the drop in HIV RNA from baseline to the nadir. In the second analysis, time to rebound was examined using Kaplan-Meier analysis, stratifying by either baseline HIV RNA or HIV RNA at the nadir. In both a...Continue Reading

References

Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·N E KohlI S Sigal
Mar 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·D J KempfX P Kong
Jun 1, 1996·Nature Medicine·M S SaagP A Volberding

❮ Previous
Next ❯

Citations

Aug 11, 2005·Current HIV/AIDS Reports·Joel E Gallant
Nov 30, 2000·Current Infectious Disease Reports·M Holodniy
Mar 11, 1998·Lancet·A Pozniak
Oct 1, 1998·Antiviral Research·A MollaD J Kempf
May 25, 1999·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·R W Shafer, D A Vuitton
Sep 21, 2001·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·A M MijchS L Wesselingh
Jul 20, 2002·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·D PillayUNKNOWN Public Health Laboratory Service Advisory Committee on Virology
Mar 21, 2002·The Lancet Infectious Diseases·Annemarie M C van RossumRonald de Groot
Dec 12, 2001·HIV Medicine·UNKNOWN BHIVA Writing Committee, UNKNOWN BHIVA Executive Committee
Sep 27, 2003·HIV Medicine·A PozniakUNKNOWN BHIVA Writing Committee BHIVA Executive Committee
Aug 11, 2001·The New England Journal of Medicine·M A AlbrechtUNKNOWN AIDS Clinical Trials Group 364 Study Team
Feb 11, 2005·The New England Journal of Medicine·Gillian D SandersDouglas K Owens
Jun 22, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S G Deeks
Jun 22, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A O'Brien
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard E NettlesRobert F Siliciano
Jan 15, 2008·The Journal of Infectious Diseases·Joel E Gallant
May 15, 2001·AIDS Research and Human Retroviruses·M NúñezV Soriano
Oct 29, 2000·AIDS Patient Care and STDs·M Núñez, V Soriano
Jan 18, 2002·Antimicrobial Agents and Chemotherapy·G L DrusanoJ A Bilello
Oct 29, 2003·Journal of Virology·Michele Di MascioAlan S Perelson
May 24, 2000·Journal of Clinical Pathology·M Helbert, J Breuer
Mar 23, 2000·The Journal of Clinical Investigation·G P RizzardiG Pantaleo
Mar 23, 2000·The Journal of Clinical Investigation·O J Cohen, A S Fauci
Aug 23, 2003·American Journal of Clinical Pathology·Estelle M Piwowar-ManningJ Brooks Jackson
Jun 19, 2008·Annals of Internal Medicine·Gillian D SandersDouglas K Owens
Dec 24, 1998·Lancet·J S MontanerM O'Shaughnessy
Aug 21, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Stephen P RaffantiUNKNOWN Collaborations in HIV Outcomes Research/United States Project
Mar 27, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·V Miller
Jul 5, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Rodolphe ThiébautUNKNOWN Groupe d'Epidémiologie Clinique du SIDA en Aquitaine
Jul 19, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Harry MichelmoreMarijka Batterham
Aug 10, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·M M KitahataA W Shields

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.